Predicting Response to Therapy | Accelerating Clinical Trials
At Cellular Analytics, our comprehensive technological solutions accelerate drug development and commercialization by providing valuable insight on patient subpopulations. Our proprietary non-invasive approach allows us to capture, identify, and analyze proteins on all tumor and immune cells at the single-cell level and link response to patient phenotype.
CytoFind™ will alter the therapeutic landscape by improving drug compatibility, ultimately increasing patient survival. This approach is not incremental, but rather a quantum improvement that will produce real value for Cellular Analytics partners.
Cellular Analytics obtained seed funding from FACIT and is affiliated with MaRS and Johnson & Johnson Innovation (JLABS).
To learn more about CytoFind™, please download the technology brief.
If you are interested in partnering with our team, please contact us.